Caution advised in patients receiving alpha adrenergic receptor antagonists for cardiovascular disease or benign prostatic hypertrophy.
Source: NLP:oxymetazoline hydrochloride ophthalmic
Brand names: Upneeq
Route: Ophthalmic
Contraindications
4 CONTRAINDICATIONS None. None. ( 4 )
Pregnancy & Breastfeeding
8.1 Pregnancy Risk Summary There are no available data on UPNEEQ use in pregnant women to inform a drug-associated risk for major birth defects and miscarriage. In animal reproduction studies, there were no adverse developmental effects observed after oral administration of oxymetazoline hydrochloride in pregnant rats and rabbits at systemic exposures up to 7 and 278 times the maximum recommended human ophthalmic dose (MRHOD), respectively, based on dose comparison. [see Data] . The estimated background risks of major birth defects and miscarriage for the indicated population are unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Animal Data Effects on embryo-fetal development were evaluated in rats and rabbits following oral administration of oxymetazoline hydrochloride during the period of organogenesis. Oxymetazoline hydrochloride did not cause adverse effects to the fetus at oral doses up to 0.2 mg/kg/day in pregnant rats during the period of organogenesis (28 times the MRHOD, on a dose comparison basis). Oxymetazoline hydrochloride did not cause adverse effects to the fetus at oral doses up to 1 mg/kg/day in pregnant rabbits during the period of organogenesis (278 times the MRHOD, on a dose comparison basis). Maternal toxicity, including decreased maternal body weight, was produced at the high dose of 1 mg/kg/day in pregnant rabbits and was associated with findings of delayed skeletal ossification. In a rat prenatal and postnatal development study, oxymetazoline hydrochloride was orally administered to pregnant rats once daily from gestation day 6 through lactation day 20. Maternal toxicity was produced at the high dose of 0.2 mg/kg/day (28 times the MRHOD, on a dose comparison basis) in pregnant rats and was associated with an increase in pup mo
5 interactions on record
Caution advised in patients receiving alpha adrenergic receptor antagonists for cardiovascular disease or benign prostatic hypertrophy.
Source: NLP:oxymetazoline hydrochloride ophthalmic
Alpha-adrenergic agonists may impact blood pressure; caution advised when using anti-hypertensives concurrently.
Source: NLP:oxymetazoline hydrochloride ophthalmic
Alpha-adrenergic agonists may impact blood pressure; caution advised when using cardiac glycosides concurrently.
Source: NLP:oxymetazoline hydrochloride ophthalmic
Caution advised in patients taking MAO inhibitors which can affect metabolism and uptake of circulating amines.
Source: NLP:oxymetazoline hydrochloride ophthalmic
Alpha-adrenergic agonists may impact blood pressure; caution advised when using beta-blockers concurrently.
Source: NLP:oxymetazoline hydrochloride ophthalmic